BioSpace News Archive

Lupin Pharmaceuticals’ recall of Tydemy birth control is the latest in a string of problems with India-based generic drug manufacturers.

Bristol Myers Squibb announced Monday that Reblozyl is now approved as a first-line treatment for adults with anemia due to myelodysplastic syndromes who may require regular blood transfusions.

The company’s investigational electric field therapy was unable to elicit significant survival benefits in patients with platinum-resistant ovarian cancer.

Data from the first-in-human trial showed that Eli Lilly’s muvalaplin is safe and can cut significant levels of lipoprotein(a), a risk factor for atherosclerosis and related cardiovascular diseases.

Warning signs that preceded the current economic squeeze in the biopharma sector were not heeded by investors seeking rapid profits. Now, biotechs interested in making the leap to the public markets must get creative.

The Biden administration on Tuesday released a much-anticipated list of the first 10 medicines included in Medicare’s Drug Price Negotiation Program under the Inflation Reduction Act.

Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces unaudited half-year financial results for January 1 to June 30, 2023.

Innate Pharma SA announced that members of its senior management team are scheduled to participate in upcoming investor conferences, detailed below.

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced that Guido Baechler, Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference taking place September 11-13, 2023 in New York, NY, USA.

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, confirmed that it is aware of an unsolicited partial tender offer from Alternative Liquidity Index LP to purchase up to a maximum of 10,000,000 shares of the Company, representing approximately 10.05% of the Company’s outstanding shares, for $0.03 per share in cash.